ROS1 and non-small cell lung carcinoma: ROS1-tyrosine kinase inhibitors (TKIs) such as crizotinib, entrectinib, and repotrectinib are effective against NSCLC harboring these common ROS1 fusion genes and are recommended as the first-line treatment [[4], [5], [6]].